| Title | Targeting Mutant KRAS for Immunogenic Cell Death Induction. |
| Publication Type | Journal Article |
| Year of Publication | 2020 |
| Authors | Galluzzi L |
| Journal | Trends Pharmacol Sci |
| Volume | 41 |
| Issue | 1 |
| Pagination | 1-3 |
| Date Published | 2020 Jan |
| ISSN | 1873-3735 |
| Keywords | Antineoplastic Agents, Humans, Immunogenic Cell Death, Lung Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras) |
| Abstract | Although somatic KRAS mutations are common in human tumors, no inhibitor of mutant KRAS was clinically available until recently. Canon and colleagues describe the ability of a clinically available KRAS inhibitor to drive immunogenic cancer cell death, thus constituting a promising combinatorial partner for immune checkpoint blockers. |
| DOI | 10.1016/j.tips.2019.11.004 |
| Alternate Journal | Trends Pharmacol Sci |
| PubMed ID | 31818506 |